For the Inventor, By the Inventor

Enter assignee name

Summit, NJ, United States of America

Novartis Corporation

USPTO Granted Patents = 166

% Expired Patents = 3.0

Trademarks = 19

Forward Citations = 3,180

Loading Chart...

Loading Chart...

340 inventors (with patents filed for the assignee):

Peter Maienfisch (6 out of 103 patents)

Norman Hardman (5 out of 8 patents)

Stephan Trah (4 out of 46 patents)

4. Hugo Ziegler (4 out of 39 patents)

5. Hans-Georg Brunner (4 out of 48 patents)

6. Laurenz Gsell (4 out of 64 patents)

7. Steven C Clark (4 out of 33 patents)

8. Elizabeth A Wang (4 out of 31 patents)

9. Nico Cerletti (4 out of 8 patents)

10. Cosima Nuninger (4 out of 9 patents)

11. Dino Sozzi (4 out of 9 patents)

12. Rene Zurfluh (4 out of 11 patents)

13. Georg Pissiotas (4 out of 91 patents)

14. John Edward Goggin (4 out of 5 patents)

15. Randal J Kaufman (4 out of 20 patents)

Core Competencies:

Osteoporosis Treatments

Monoclonal Antibodies

Ocular Sensors

Fungicidal Compositions

Insecticidal Matrix

Transgenic Drosophila

Biologically Active Proteins

Pharmaceutical Compositions

Herbicidal Compositions

Optical Sensors

Growth Factor Receptors

Antiviral Ethers

166 patents: Sort by Forward Citations

1. 8119105 - Aerosol container and a method for storage and administration of a pre-determined amount of a pharmaceutically active aerosol (2012-02-21),

2. 7465723 - Use of carboxamides for the treatment of tinnitus (2008-12-16),

3. 7253257 - Human metabotropic glutamate receptor subtype mGluR7b (2007-08-07),

4. 7057016 - Process for the production of biologically active protein (2006-06-06),

5. 6980842 - Ocular analyte sensor (2005-12-27),

6. 6900367 - Transgenic Drosophila melanogaster expressing a β42 in the eye (2005-05-31),

7. 6833241 - Mammary gland chemokine (2004-12-21),

8. 6596260 - Aerosol container and a method for storage and administration of a predetermined amount of a pharmaceutically active aerosol (2003-07-22),

9. 6515107 - Human metabotropic glutamate receptor 7 subtypes (2003-02-04),

10. 6358925 - Method and composition for the treatment of osteoporosis (2002-03-19),

11. 6300309 - Method and composition for the treatment of osteoporosis (2001-10-09),

12. 6294656 - Transforming growth factor &bgr; crystals (2001-09-25),

13. RE37344 - Ferrocenyl diphosphines as ligands for homogeneous catalysts (2001-08-28),

14. 6255288 - Certain methanebisphosphonic acid derivatives in fracture healing (2001-07-03),

15. 6228610 - Human metabotropic glutamate receptor subtypes (hmR4, hmR6, hmR7) and related DNA compounds (2001-05-08),

Company Overview

Novartis Corporation, headquartered in Summit, NJ, is a leader in pharmaceutical innovation, focusing on developing advanced treatments for various medical conditions. The company specializes in areas such as osteoporosis treatments, monoclonal antibodies, and ocular sensors, among others. Its research encompasses a wide range of core technology topics, including fungicidal compositions, insecticidal matrices, and biologically active proteins, positioning Novartis at the forefront of biopharmaceutical advancements.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 13 2026

166 Patents

#2 in Summit, NJ

#111 in New Jersey

#2,398 in US

#4,976 in the World

Summit, NJ, United States of America

Novartis Corporation

Forward Citations = 3,180

340 inventors:

Peter Maienfisch (6 out of 103 patents)

Norman Hardman (5 out of 8 patents)

Stephan Trah (4 out of 46 patents)

4. Hugo Ziegler (4 out of 39 patents)

5. Hans-Georg Brunner (4 out of 48 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Novartis Corporation. Retrieved from https://idiyas.com/company/novartis

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

Loading…